Robert Sebra, PhD, is a Professor in the Department of Genetics and Genomic Sciences, Director of The Center for Advanced Genomics Technology, and Director of Technology Development for the Genomics Core Facility at the Icahn School of Medicine at Mount Sinai. He is a faculty member of the Icahn Genomics Institute. His research lab centers on creating and applying bulk and single cell molecular methods to generate highly resolved data using genomics technology for variant discovery and annotation. This research integrates single molecular and cellular genomics data with assays to assess chromatin accessibility, proteomics, and epigenetics data to decipher factors of pathogenesis versus normal cellular functions. Determining which cellular niches and mechanisms in complex primary tissues drive disease or resilience facilitates translation of functional genomics data using model systems for screening possible downstream regenerative and therapeutic potential using high throughput methods.
Ongoing research interests include:
- Developing novel molecular methods and genome sequencing technologies
- Advancing high-throughput functional genomics
- Exploring whole genome and repeat content characterization for disease association
- Analyzing surveillance and genomic characterization of pathogen transmission
- Using genomics to temporally characterize development and pathogenesis
- Translating genomic data in various oncologic diseases including gynecologic and breast cancers
Multi-Disciplinary Training Areas
Development Regeneration and Stem Cells [DRS], Genetics and Genomic Sciences [GGS]Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Sebra during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Employment:
- Sema4
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.